Publications scientifiques

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

Auteurs : Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H; EXAFIP investigators and the OrphaLung network.

Sources : Lancet Respir Med. 2021 Sep 7: S2213-2600(21)00354-4.

Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort

Auteurs : Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort Cottin V, Gueguen S, Jouneau S, Nunes H, Crestani B, Bonniaud P, Wémeau-Stervinou L, Reynaud-Gaubert M, Israël-Biet D, Cadranel J, Marchand-Adam S, Quétant S, Hirschi S, Montani D, Gamez AS, Chevereau M, Dufaure-Garé I, Amselem S, Clement A; OrphaLung and RespiFil Networks.

Sources : Respiration. 2021 Sep 2:1-12.

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

Auteurs : Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD trial investigators.

Sources : Eur Respir J. 2021 Sep 2:2004538.

Robotic lobectomy in children with severe bronchiectasis: A worthwhile new technology

Auteurs : Durand M, Musleh L, Vatta F, Orofino G, Querciagrossa S, Jugie M, Bustarret O, Delacourt C, Sarnacki S, Blanc T, Khen-Dunlop N.

Sources : J Pediatr Surg. 2021 Sep;56(9):1606-1610.

Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort

Auteurs : Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Canuet M, Boissin C, Tromeur C, Chaouat A, Degano B, Bergot E, Sanchez O, Prevot G, Sitbon O, Thabut G, Belhadi D, de Beauregard YC, Bencherif A, Humbert M, Simonneau G, Laouenan C, Mal H.

Sources : J Heart Lung Transplant. 2021 Sep;40(9):1009-1018. Doi: 10.1016/j.healun.2021.04.021.

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach

Auteurs : Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, Oudot A, Helbling A, Guillemin M, Bonniaud P, Cochet A, Collin B, Bellaye PS.

Sources : Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3058-3074. Doi: 10.1007/s00259-021-05209-2.

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities

Auteurs : Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, Valenzuela C, Guler S, Jones S, Wijsenbeek M, Cottin V.

Sources : Lancet Respir Med. 2021 Sep;9(9):1065-1076. Doi: 10.1016/S2213-2600(21)00017-5.

The progressive fibrotic phenotype in current clinical practice

Auteurs : Wells AU, Brown KK, Cottin V.

Sources : Curr Opin Pulm Med. 2021 Sep 1;27(5):368-373. Doi: 10.1097/MCP.0000000000000805.

How to Tackle the Diagnosis and Treatment in the Diverse Scenarios of Extrapulmonary Sarcoidosis

Auteurs : Valeyre D, Jeny F, Rotenberg C, Bouvry D, Uzunhan Y, Sève P, Nunes H, Bernaudin JF.

Sources : Adv Ther. 2021 Sep;38(9):4605-4627. Doi: 10.1007/s12325-021-01832-5.

Drug-induced sarcoidosis-like reactions

Auteurs : Miedema J, Nunes H.

Sources : Curr Opin Pulm Med. 2021 Sep 1;27(5):439-447. Doi: 10.1097/MCP.0000000000000800.